In summary, BTK inhibitors are highly effective options for the treatment of patients with CLL, and selection is driven by patient and physician personal choice, as well as available efficacy and tolerability data from clinical trials and clinician experience. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.